-- Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization --
-- Adds novel, high-capacity, local-delivery platform for the development of genetic medicines with disease-modifying potential for prevalent musculoskeletal diseases with significant unmet needs --
Comments